Application of the QbD-based approach in the early development of liposomes for nasal administration.

In this study, authors adapt the Quality by Design (QbD) concept as well as the Risk Assessment (RA) method to the early development phase of a new nano-sized liposomal formulation for nasal administration with brain target. As a model active agent, a BCS II class drug was chosen to investigate the behaviour of the drugs with lipophilic character. This research presents how to apply this risk-focused approach and concentrates on the first four stages of the QbD implementation. In this way the quality target product profile was defined, the critical factors were identified and an RA was performed. The RA results helped in the factorial design-based liposome preparation by the lipid film hydration method. The prepared liposomes were evaluated (vesicle size, size distribution, and specific surface area). The surface characteristics were also investigated to verify the exactness of the RA and critical factors based theoretical prediction. The results confirm that the QbD approach in liposome development can improve the formulation process. The RA focused predictive approach resulted in a decreased number of studies in practice but in an effective product preparation. Using such innovative design and development models can help to optimise and rationalise the development of liposomes.

[1]  Selcan Türker,et al.  Nasal route and drug delivery systems , 2004, Pharmacy World and Science.

[2]  D. Deamer From “Banghasomes” to liposomes: A memoir of Alec Bangham, 1921–2010 , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  A. Falcão,et al.  Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice. , 2015, International journal of pharmaceutics.

[4]  G. Amidon,et al.  The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  Edina Pallagi,et al.  Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes. , 2018, Drug discovery today.

[6]  Edina Pallagi,et al.  New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach. , 2016, International journal of pharmaceutics.

[7]  Hussain,et al.  Intranasal drug delivery. , 1998, Advanced drug delivery reviews.

[8]  R. Ambrus,et al.  Preliminary study of nanonized lamotrigine containing products for nasal powder formulation , 2017, Drug design, development and therapy.

[9]  J. Veuthey,et al.  Strategies for formulating and delivering poorly water-soluble drugs , 2015 .

[10]  T. Allen,et al.  Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. , 1993, Biochimica et biophysica acta.

[11]  R. Ambrus,et al.  Investigation of Absorption Routes of Meloxicam and Its Salt Form from Intranasal Delivery Systems , 2018, Molecules.

[12]  V. Torchilin Targeted pharmaceutical nanocarriers for cancer therapy and imaging , 2007, The AAPS Journal.

[13]  L. Illum Nasal drug delivery--possibilities, problems and solutions. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Seemalata Jain,et al.  Liposomal formulation of curcumin attenuates seizures in different experimental models of epilepsy in mice , 2013, Fundamental & clinical pharmacology.

[15]  Hatem Fessi,et al.  Preparation, Characterization and Applications of Liposomes: State of the Art , 2012 .

[16]  Wei Zhang,et al.  Effect of Freezing Rate on the Stability of Liposomes During Freeze-Drying and Rehydration , 1997, Pharmaceutical Research.

[17]  Adriana O. Santos,et al.  Nanosystems in nose‐to‐brain drug delivery: A review of non‐clinical brain targeting studies , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[18]  M. Winterhalter,et al.  Liposome stability and formation: experimental parameters and theories on the size distribution. , 1993, Chemistry and physics of lipids.

[19]  Michael B. Bolger,et al.  Application of Gastrointestinal Simulation for Extensions for Biowaivers of Highly Permeable Compounds , 2008, The AAPS Journal.

[20]  J Helen Cross,et al.  Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance , 2012, BMJ : British Medical Journal.

[21]  Edina Pallagi,et al.  Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation. , 2015, International journal of pharmaceutics.

[22]  R. Ambrus,et al.  Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles. , 2015, International journal of pharmaceutics.

[23]  D. Lamprou,et al.  Influence of cholesterol on liposome stability and on in vitro drug release , 2015, Drug Delivery and Translational Research.

[24]  Amit S. Patil,et al.  Quality by Design (QbD) : A new concept for development of quality pharmaceuticals , 2013 .

[25]  O. Dulac,et al.  Lamotrigine in Treatment of 120 Children with Epilepsy , 1994, Epilepsia.

[26]  G. Colombo,et al.  Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting , 2018, Pharmaceutics.

[27]  S. Garg,et al.  Permeability issues in nasal drug delivery. , 2002, Drug discovery today.

[28]  Lawrence X. Yu Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[29]  A. Molinari,et al.  Liposomes as nanomedical devices , 2015, International journal of nanomedicine.

[30]  M. Parvathi INTRANASAL DRUG DELIVERY TO BRAIN: AN OVERVIEW , 2012 .

[31]  M. R. Mozafari,et al.  Liposomes: A Review of Manufacturing Techniques and Targeting Strategies , 2011 .

[32]  R. Ambrus,et al.  Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach , 2016, Drug design, development and therapy.

[33]  Z. Zawada A single-step method of liposome preparation. , 2004, Cellular & molecular biology letters.

[34]  Soodabeh Davaran,et al.  Liposome: classification, preparation, and applications , 2013, Nanoscale Research Letters.

[35]  G. K. Raju,et al.  Understanding Pharmaceutical Quality by Design , 2014, The AAPS Journal.